This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Moroni, M. Articles by Mueller, S. C. Search for Related Content PubMed PubMed Citation Articles by Moroni, M. Articles by Mueller, S. C.

Progressive Loss of Syk and Abnormal Proliferation in Breast Cancer Cells

Departments of ¹ Oncology, ² Pathology, ³ Biostatistics, and ⁴ Radiation Medicine, Lombardi Comprehensive Cancer Center, Georgetown University Medical School; and ⁵ Department of Pathology, MedStar, Washington, District of Columbia

The tumor suppressor gene Syk tyrosine kinase is absent or reduced in invasive breast cancer tissues and cell lines; its loss in breast tissues is linked to poor prognosis and metastasis. Also, evidence shows that in vitro Syk is involved in regulating proliferation. Here, we show by in situ hybridization on breast tissue sections that the loss of Syk expression is progressive during tumor development. Strikingly, Syk is already partially lost in normal epithelial tissue adjacent to the cancer lesion. In vivo, cell proliferation (as measured by the proliferative index Ki67) increased from normal to ductal carcinoma in situ to invasive, whereas Syk in situ staining in the same tissues decreased. In vitro, the presence of Syk was associated with reduced cell proliferation in an epidermal growth factor receptor-overexpressing breast cancer cell line, BT549, whereas changes in apoptosis were undetected. Concomitantly, the kinase activity of the proto-oncogene Src was reduced by 30%. A 5-fold increase in abnormal mitoses was observed in the Syk-transfected cells compared with vector control. We propose that Syk is involved in the regulation of cell proliferation, possibly by controlling mechanisms of mitosis and cytokinesis via Src signal transduction pathway(s). Because of its progressive and early loss during tumor onset and development, monitoring of Syk loss in breast epithelial cells by noninvasive techniques such as ductal lavage may be a powerful tool for screening purposes.

This article has been cited by other articles:

				S. Luangdilok, C. Box, L. Patterson, W. Court, K. Harrington, L. Pitkin, P. Rhys-Evans, P. O-charoenrat, and S. Eccles Syk Tyrosine Kinase Is Linked to Cell Motility and Progression in Squamous Cell Carcinomas of the Head and Neck Cancer Res., August 15, 2007; 67(16): 7907 - 7916. [Abstract] [Full Text] [PDF]

				T. Wossning, S. Herzog, F. Kohler, S. Meixlsperger, Y. Kulathu, G. Mittler, A. Abe, U. Fuchs, A. Borkhardt, and H. Jumaa Deregulated Syk inhibits differentiation and induces growth factor-independent proliferation of pre-B cells J. Exp. Med., December 25, 2006; 203(13): 2829 - 2840. [Abstract] [Full Text] [PDF]

				Y. Yuan, J. Wang, J. Li, L. Wang, M. Li, Z. Yang, C. Zhang, and J. L. Dai Frequent Epigenetic Inactivation of Spleen Tyrosine Kinase Gene in Human Hepatocellular Carcinoma. Clin. Cancer Res., November 15, 2006; 12(22): 6687 - 6695. [Abstract] [Full Text] [PDF]

				F. J. Delfino, H. Stevenson, and T. E. Smithgall A Growth-suppressive Function for the c-Fes Protein-Tyrosine Kinase in Colorectal Cancer J. Biol. Chem., March 31, 2006; 281(13): 8829 - 8835. [Abstract] [Full Text] [PDF]

				D. Zyss, P. Montcourrier, B. Vidal, C. Anguille, F. Merezegue, A. Sahuquet, P. H. Mangeat, and P. J. Coopman The Syk Tyrosine Kinase Localizes to the Centrosomes and Negatively Affects Mitotic Progression Cancer Res., December 1, 2005; 65(23): 10872 - 10880. [Abstract] [Full Text] [PDF]

				L. Wang, E. Devarajan, J. He, S. P. Reddy, and J. L. Dai Transcription Repressor Activity of Spleen Tyrosine Kinase Mediates Breast Tumor Suppression Cancer Res., November 15, 2005; 65(22): 10289 - 10297. [Abstract] [Full Text] [PDF]

				W. Sangrar, R. A. Zirgnibl, Y. Gao, W. J. Muller, Z. Jia, and P. A. Greer An Identity Crisis for fps/fes: Oncogene or Tumor Suppressor? Cancer Res., May 1, 2005; 65(9): 3518 - 3522. [Abstract] [Full Text] [PDF]